This prospective study aims to examine the association of specific genetic variants (single nucleotide polymorphisms) located on chromosome 1, 4 and 16, with presence of non-pulmonary vein triggers (NPVT) as well as ablation-outcome in AF patients

NCT01751607

Conditions

1. Atrial Fibrillation

MeSH:Atrial Fibrillation

HPO:Atrial fibrillation Paroxysmal atrial fibrillation

Previous left atrial catheter ablation or MAZE procedure 2. Reversible causes of atrial arrhythmia such as hyperthyroidism, sarcoidosis, pulmonary embolism etc Atrial Fibrillation Atrial Fibrillation Specific Aim: This prospective pilot study aims to examine the association of specific genetic variants (single nucleotide polymorphisms) namely rs2200733, rs6843082, rs10033464, rs17042171, rs2106261 and rs13376333 on chromosome 1, 4 and 16, with presence of non-pulmonary vein triggers (NPVT) as well as ablation-outcome in AF patients.

Atrial fibrillation (AF) is the significant risk factor of ischemic stroke with incidence about 20% of all ischemic strokes. The undiagnosed AF in cryptogenic stroke patients could be present but not revealed by rutinne ECG.

NCT02216370

Conditions

1. Cryptogenic Stroke or TIA
2. Atrial Fibrillation

MeSH:Stroke Atrial Fibrillation

HPO:Atrial fibrillation Paroxysmal atrial fibrillation Stroke

Documented Atrial Fibrillation after episode of cryptogenic stroke / TIA Documented genetic mutation PITX2 chromosome 4q25, polymorphism rs1906591,rs10033464 and ZFHX3 chromosome 16q22, polymorphism rs2106261.

In this pilot and feasibility study, the investigators will enroll patients with frequent symptomatic episodes of atrial fibrillation (AF) in a cross-over study testing two different classes of anti arrhythmic drugs (AADs). This pilot and feasibility study will provide preliminary data for a larger study in which the investigators will test the hypothesis that a common AF genetic risk allele modulates response to different AADs.

NCT02347111

Conditions

1. Atrial Fibrillation

Interventions

1. Drug: Flecainide
2. Drug: Sotalol

MeSH:Atrial Fibrillation

HPO:Atrial fibrillation Paroxysmal atrial fibrillation

However, a SNP at the 4q25 locus (rs10033464) was significantly associated with successful symptom control (odds ratio [OR] 2.97, 95% confidence interval [CI] 1.42-6.21,

As the minor allele frequency (MAF) of rs10033464 is ~12%, the ratio of carriers to non-carriers is ~1:8.

For the primary analysis, we will test the hypothesis that the chr4q25 AF risk allele (rs10033464) modulates the treatment effect difference between flecainide and sotalol.